Neumora Therapeutics (NASDAQ:NMRA) Insider Paul Berns Sells 9,819 Shares of Stock

Neumora Therapeutics, Inc. (NASDAQ:NMRA) insider Paul Berns sold 9,819 shares of the business’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $3.51, for a total value of $34,464.69. Following the completion of the transaction, the insider owned 7,395,185 shares in the company, valued at approximately $25,957,099.35. This trade represents a 0.13% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Neumora Therapeutics Stock Down 2.7%

NASDAQ NMRA traded down $0.10 during mid-day trading on Friday, reaching $3.39. 364,898 shares of the company’s stock traded hands, compared to its average volume of 2,272,368. The company has a current ratio of 6.85, a quick ratio of 6.85 and a debt-to-equity ratio of 0.15. Neumora Therapeutics, Inc. has a 1-year low of $0.61 and a 1-year high of $3.65. The company has a fifty day simple moving average of $2.18 and a 200-day simple moving average of $2.06. The company has a market cap of $565.60 million, a price-to-earnings ratio of -2.30 and a beta of 3.20.

Analysts Set New Price Targets

Several analysts recently issued reports on NMRA shares. Needham & Company LLC upped their price target on shares of Neumora Therapeutics from $6.00 to $8.00 and gave the company a “buy” rating in a report on Tuesday, October 28th. Stifel Nicolaus boosted their target price on shares of Neumora Therapeutics from $2.00 to $3.00 and gave the stock a “hold” rating in a research report on Monday, November 17th. Royal Bank Of Canada raised shares of Neumora Therapeutics from a “sector perform” rating to an “outperform” rating and increased their price target for the stock from $4.00 to $7.00 in a research report on Monday, December 1st. Mizuho set a $6.00 price target on Neumora Therapeutics in a research note on Monday, January 5th. Finally, Leerink Partners assumed coverage on Neumora Therapeutics in a research note on Monday, January 12th. They set an “outperform” rating and a $8.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $8.13.

Hedge Funds Weigh In On Neumora Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of NMRA. AlphaCore Capital LLC bought a new position in shares of Neumora Therapeutics during the second quarter worth about $248,000. Catalyst Funds Management Pty Ltd bought a new stake in Neumora Therapeutics in the 2nd quarter valued at about $29,000. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in Neumora Therapeutics during the 2nd quarter valued at about $41,000. Savant Capital LLC bought a new position in Neumora Therapeutics in the 2nd quarter worth about $52,000. Finally, Y Intercept Hong Kong Ltd acquired a new stake in shares of Neumora Therapeutics in the second quarter valued at approximately $42,000. 47.65% of the stock is currently owned by institutional investors and hedge funds.

Neumora Therapeutics Company Profile

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.